FDA Approved 16 New or Expanded Cancer Therapies
New treatments and detection tools reached patients as cancer research continues to advance across the U.S.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Should the nation increase funding for medical research to accelerate breakthroughs in cancer treatment?
The American Association for Cancer Research released its 2026 Cancer Progress Report, which notes that the FDA approved 11 new anticancer drugs and expanded the uses for five existing therapies between July 2025 and June 2026. These developments represent a shift in how clinicians and patients in the United States approach cancer management.
Why it matters
These regulatory approvals expand the toolkit available for oncologists to treat specific cancer types, while new diagnostic AI tools may shift the focus toward earlier detection. Understanding these advancements is essential for patients navigating changing treatment options or new diagnostic protocols.
The 2026 Cancer Progress Report catalogs 11 new anticancer therapeutics and five expanded therapeutic indications approved by the FDA. While these figures summarize recent regulatory activity, the long-term clinical efficacy and population-level impact of these tools are currently under review.
The players
American Association for Cancer Research
A scientific organization that drives cancer research and provides data on treatment advancements.
Food and Drug Administration
The federal agency responsible for evaluating the safety and efficacy of new medical therapies and diagnostic devices.
The details
The recent approvals include a wearable, noninvasive device for treating pancreatic cancer and several AI-powered tools designed to assist in early diagnosis. Researchers are also actively evaluating the role of glucagon-like peptide-1 receptor agonists in oncology research to see if their metabolic effects influence cancer progression. These advancements underscore a trend toward integrating precision technology and repurposed pharmaceutical agents into standard oncology care.
Timeline
July 1, 2025: The FDA began tracking data for these specific anticancer therapeutic approvals.
June 30, 2026: Data collection for the approved therapies concluded.
September 28, 2026: The American Association for Cancer Research released the 2026 Cancer Progress Report.
Health Landscape
The FDA approvals follow the historical reporting trends established by the AACR Cancer Progress Report. This report documents an ongoing increase in FDA-approved cancer therapies and diagnostic innovations compared to prior years.
These new approvals may eventually change the standard of care for certain cancer diagnoses, making it important to discuss any new treatment or screening options with your oncologist. If you are currently in treatment or at high risk, consult your doctor about whether emerging therapies or AI-assisted diagnostic tools are appropriate for your specific case.
The takeaway
The recent wave of FDA approvals highlights a rapid evolution in both cancer treatment and early detection technology. Patients should track these updates to have more informed conversations with their healthcare providers regarding the latest options available for their specific health status.
Further reading
For more information on how new breakthroughs are changing clinical practice, visit our Cancer section.
Source note: This article includes information reported by Oncology Nurse Advisor.
Live Poll
Should the nation increase funding for medical research to accelerate breakthroughs in cancer treatment?
